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Endothelin-1 (ET-1) and its receptors (ETAR and ETBR), referred to as the endothelin (ET) axis, are overexpressed in breast
carcinomas and appear to influence tumour growth and progression. The objective of this study was to determine the effect of
expression of the ET axis in breast carcinomas on response to cytotoxic chemotherapy. The study included 44 patients with locally
advanced breast cancer participating in a prospective phase III study evaluating high-dose neoadjuvant chemotherapy of epirubicin
and cyclophosphamide. Expression of ET-1, ETAR and ETBR was determined by semiquantitative immunohistochemical analysis of
breast cancer tissue from prechemotherapy tru-cut biopsies. Immunohistochemical staining was positive for ET-1 in 61.5%, for ETAR
in 35% and for ETBR in 35.9% of breast carcinomas. Pathological response to chemotherapy was significantly decreased in ETAR-
positive patients (P¼0.002). In total, 50% of ETAR-positive patients as compared to 7.7% of ETAR-negative patients attained
pathologically ‘no change’. Logistic regression confirmed ETAR as an independent predictive marker for pathological response
(P¼0.009). These data indicate that increased expression of ETAR in breast carcinomas is associated with resistance to
chemotherapy. Determination of ETAR status may serve as a predictive marker for identifying patients less likely to be responsive to
conventional chemotherapy.
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Breast cancer is the most common cancer in women worldwide
and distant metastases are the leading cause of breast cancer
related death (Ferlay et al, 2000). Thus, adjuvant systemic therapy
has become the standard therapy to destroy residual or
disseminated tumour cells. Neoadjuvant chemotherapy has been
developed to improve breast-conserving operability in locally
advanced breast cancers. Results from the NSABP B-18 study
confirmed that neoadjuvant and adjuvant chemotherapy are
equally effective on locoregional disease in women with operable
breast cancer. Moreover, this study demonstrated that clinical and
pathological response to neoadjuvant chemotherapy is predictive
of patient outcome (Fisher et al, 1997, 1998). However, the failure
of a number of tumours to respond to treatment and the
appearance of resistant tumour cell populations upon relapse of
an originally responsive malignancy are still major impediments to
successful chemotherapy. Currently, no tumour marker is available
for clinical use in predicting chemotherapy response in breast
cancer. It is thus an important goal in oncologic research to
identify molecular markers to facilitate risk-adapted individual
therapy concepts.
The endothelins (ETs) comprise three 21 amino-acid peptides,
ET-1, ET-2, and ET-3, which are multifunctional peptides with
diverse activity (Yanagisawa et al, 1988). ET-1 is expressed
primarily by endothelial, vascular smooth muscle and epithelial
cells, whereas ET-2 and ET-3 are expressed in kidney epithelial
cells and in gastrointestinal stromal cells (Levin, 1995; Nelson et al,
2003). Of the three ET isoforms, ET-1 has been the most
extensively studied, and appears to be the most important isoform
in cancer pathophysiology (Grant et al, 2003; Nelson et al, 2003).
ET-1 expression is increased in several human malignancies
including ovarian, prostate and colorectal cancer (Nelson et al,
1996, 2003; Salani et al, 2000; Asham et al 2001). Upregulation of
ET-1 occurs in response to cell activation and is induced by
various stimuli such as hypoxia, growth factors, and cytokines
(Kourembanas et al, 1991). ET-1 effects are mediated through two
subtypes of G protein-coupled receptors, ETAR and ETBR. ETAR
binds ET-1 and ET-2 with high affinity and ET-3 with low affinity,
whereas ETBR is nonselective with equal affinity for the three
subtypes (Rubanji and Polokoff, 1994). It has been shown that ET-
1 competitively binds to the ETA- and ETB-receptor, although
ETAR is the dominant receptor (Bagnato et al, 1995, 1999). The
complex of ET-peptides and ET receptors is referred to as the ‘ET
axis’ (Nelson and Carducci, 1999). With respect to ET receptors,
predominantly ETAR mediates tumour-associated functions,
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lwhereas there is less evidence for ETBR-dependent tumour-related
functions (Grant et al, 2003; Nelson et al, 2003). Engagement of
ETA-receptor by ET-1 triggers tumorigenesis and tumour progres-
sion by activation of tumour proliferation, invasion, angiogenesis,
and inhibition of apoptosis (Pedram et al, 1997; Bagnato and Catt,
1998; Bagnato et al, 1999; Eberl et al, 2000b; Salani et al, 2000;
Rosano et al, 2001; Del Bufalo et al, 2002). There is also evidence
for an autocrine and/or paracrine mechanism of action of ET-1
including angiogenesis-promoting effects in malignant tissues. It
has been shown that ET-1 induces endothelial cell growth through
ETBR and exerts mitogenic effects on vascular smooth muscle cells
and pericytes through ETAR (Bek and McMillen, 2000; Salani et al,
2000). Moreover, activation of ETAR by ET-1 stimulates the
production of VEGF, which in turn induces endothelial cell
proliferation and vascular permeability by increasing the levels of
HIF-1a (Spinella et al, 2002). In addition to its mitogenic effects,
ET-1 has also been found to contribute to tumour growth by
protecting tumour cells from apoptosis (Eberl et al, 2000b).
Increased ETAR expression has been demonstrated in malignant
tissue in several cancer types including ovarian, prostate and
colorectal cancer, whereas in normal tissue from these sites ETBR
predominates (Nelson et al, 1996; Bagnato et al, 1999; Ali et al,
2000).
Studies have investigated expression of ET-1 in human breast
carcinoma by applying radioimmunoassay (Yamashita et al, 1991;
Yamashita et al, 1995), immunohistochemistry (Kojima and Nihei,
1995; Alanen et al, 2000), and quantitative RT–PCR (Alanen et al,
2000). Consistent with other reports on altered ET axis in breast
cancer (Yamashita et al, 1991; Alanen et al, 2000), we have
previously demonstrated an increased ET-1, ETAR, and ETBR
expression in human breast carcinomas (Wu ¨lfing et al, 2003). In
our series, overexpression of ET-1, ETBR and especially of ETAR
was associated with clinicopathological parameters that character-
ise aggressive types of breast cancer and indicated a poor outcome,
whereas other studies failed to confirm such correlations. In view
of the above findings, the ET axis and especially ETAR has been
proposed as a potential target for anticancer therapy (Bagnato et al,
2002; Pirtskhalaishvili and Nelson, 2002; Rosano et al, 2003).
Various biological markers are currently being investigated as
predictors of chemotherapy response in breast cancer. Such factors
may be used in the selection of neoadjuvant or adjuvant
chemotherapeutic treatment. Indeed, biological markers with
confirmed prognostic or predictive impact could also serve as
targets for therapeutic compounds to improve current breast
cancer therapies. Thus, the objective of the present study was to
investigate the predictive value of the ET axis for response to
neoadjuvant chemotherapy in patients treated for locally advanced
breast cancer. As the vast majority of studies in the literature
dealing with ET expression in malignancies showed the predomi-
nant role of the ET-1 isoform and the ETA-receptor, this study
focused on the expression of these markers.
PATIENTS AND METHODS
Patients
A total of 44 patients diagnosed with locally advanced breast
cancer (T2–4N0–2M0) participating in a prospective randomised
phase III study evaluating a high-dose neoadjuvant chemotherapy
consisting of epirubicin (Pharmacia GmbH, Erlangen, Germany)
and cyclophosphamide (Baxter, Frankfurt, Germany) were in-
cluded in the study (Euler et al, 2002). Patients were diagnosed and
treated at the Department of Obstetrics and Gynecology, Klinikum
Bayreuth, Germany, between August 1997 and March 2002. Their
median age was 51 years (range, 29–66 years). None of the patients
had objective skin inflammation or oedema. On first presentation,
a tru-cut biopsy was performed to confirm the diagnosis
histologically. Initial staging was comprised of clinical examina-
tion, bilateral mammography, bilateral breast sonography, sono-
graphy of the axillary region, chest X-ray, liver sonography, and
bone scintigraphy. Table 1 lists the results of the clinically assessed
pretherapeutic tumour size and lymph node status.
Tumour samples
Prechemotherapy tissue samples obtained by tru-cut biopsy were
processed by formaldehyde fixation and paraffin embedding.
Oestrogen receptor (ER) and progesterone receptor (PgR) status,
Table 1 Characteristics of patients and tumours at the time of diagnosis
(prior to neoadjuvant chemotherapy)
No. of patients 44
Age (years)
Median (range) 51 (29–66)
Menopausal status
Premenopausal 15 (34.9%)
Postmenopausal 28 (65.1%)
Unknown 1
Tumour size
T2 39 (90.7%)
T3 3 (7%)
T4 1 (2.3%)
Unknown 1
Lymph node status
N0 24 (57.1%)
N1 18 (42.9%)
Unknown 2
Grading
a
I 1 (2.7%)
II 12 (32.4%)
III 24 (64.9%)
Unknown 7
Histology
Ductal 29 (65.9%)
Lobular 11 (25%)
Other 4 (9.1%)
Oestrogen receptor
Negative 9 (21.4%)
Positive 33 (78.6%)
Unknown 2
Progesterone receptor
Negative 12 (28.6%)
Positive 30 (71.4%)
Unknown 2
Her-2/neu
Negative 29 (70.7%)
Positive 12 (29.3%)
Unknown 3
Ki67
o18% 17 (41.5%)
X18% 24 (58.5%)
Unknown 3
p53
Normal 28 (68.3%)
Mutation 13 (31.7%)
Unknown 3
aGrading of surgical resection specimens postchemotherapy; not applicable in seven
patients.
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lp53, Her-2/neu and Ki67 were assessed immunohistochemically.
Analyses were performed by Dianon Systems, Inc. (Stratford, CT,
USA), and Molecular Oncology International P.S. (Seattle, WA,
USA) using scoring criteria suggested by these laboratories.
Oestrogen receptor and PgR status were considered positive if
X10% of tumour cells stained positive. High proliferative activity
was defined as X18% of tumour cell nuclei stained with
monoclonal antibodies (AB) against the Ki-67 antigen. Her-2/neu
expression and p53 mutation were considered positive if X10% of
infiltrating tumour cells stained positive with at least moderate
intensity. Details are given in Table 1.
Treatment protocol
The study protocol was approved by the institutional review board
(ethical committee, University of Nu ¨rnberg-Erlangen, Germany),
and their informed consent was obtained. Neoadjuvant che-
motherapy consisted of epirubicin (120mgm
 2) and cyclopho-
sphamide (600mgm
 2) per cycle. Cycles were repeated every 2
weeks (arm A) or every 3 weeks (arm B) (21 out of 44 patients were
randomised for arm A, 23 out of 44 for arm B). For patients in arm
A, chemotherapy was followed by 5mgkg
 1day
 1 GM-CSF
(AMGEN, Mu ¨nchen, Germany) s.c. or i.v. on days 2–12 after each
cycle. For arm B, supportive GM-CSF was required if leucocytes
were o2000ml
 1. The sizes of primary tumours and of axillary
lymph nodes, when applicable, were measured every cycle by
palpation and by the same clinician using a calliper. To assess the
clinical response, changes in the product of the two largest
diameters recorded as baseline and at the end of chemotherapy
prior to surgery were measured. Additionally, tumour size was
evaluated using sonography and mammography. Clinical response
to chemotherapy was classified according to the criteria of the
International Union Against Cancer (UICC) as follows: (i)
complete response (CR), disappearance of all clinical signs of
disease; (ii) partial response (PR), X50% decrease in tumour size;
(iii) no change (NC), clinically o50% decrease or o25% increase
in tumour size; (iv) progressive disease (PD), X25% increase in
tumour size or appearance of new lesions (Hayward et al, 1977).
At 2 or 3 weeks after the third cycle of chemotherapy surgery
was planned. Patients who showed any clinical response to the
treatment (n¼40) underwent breast-conserving surgery and
irradiation of the residual breast (60Gy delivered in 6 weeks). In
nine of these patients, reconstruction of the breast had to be
performed concomitantly (latissimus dorsi flap). Four patients
without any regression of the tumour had a modified radical
mastectomy.
Pathological response to preoperative chemotherapy was
categorised semiquantitatively into four groups, according to the
literature (Sinn et al, 1994): no effect (¼grade 0); resorption and
tumour sclerosis (¼grade 1); minimal residual invasive tumour
o0.5cm (¼grade 2); residual noninvasive tumour only (¼grade
3); no tumour detectable (¼grade 4). The final pathological
response was designated as follows: grade 0, NC; grade 1–3, PR;
grade 4, CR. Patients with pathological response to neoadjuvant
chemotherapy (CR or PR) postoperatively received a fourth cycle
of high-dose epirubicin and cyclophosphamide (EC) and subse-
quently two cycles of a cyclophosphamide-, methotrexate-, 5-
fluorouracil (CMF)-containing regimen (methotrexate: medac,
Hamburg, Germany; 5-fluorouracil: GRY-Pharma, Kirchzarten,
Germany). In total, 12 cycles of 5-FU (2gm
 2, weekly) and four
cycles of Taxol (Bristol-Meyers-Squibb, Mu ¨nchen, Germany)
(Taxol¼175mgm
 2, every 3 weeks) were given to pathological
nonresponders (Klaassen et al, 1998).
Preparation of surgical resection specimens
The surgical resection specimens at breast-conserving therapy or
mastectomy were examined and cut up fresh.
Appropriate tissue blocks were routinely processed, fixed in
formalin, and embedded in paraffin. Serial 3-mm sections were cut
and stained with haematoxylin and eosin. Tumour size (pT
classification) was measured macroscopically on stained serial
sections containing the largest tumour specimen, or estimated on
the basis of a sequential series of slides. The cases were classified
according to the TNM classification (UICC, 5th edition). Tumour
grade was also assigned based on the UICC criteria, dividing
tumours into grade I (well differentiated), grade II (moderately
differentiated), and grade III (poorly differentiated). Pathological
response was determined as described above. All cases were
reviewed by two experienced pathologists.
Immunohistochemistry for ET-1, ETAR, and ETBR
expression
Since we wanted to investigate whether the ET axis has a predictive
value for chemotherapy response, immunohistochemical analysis
was carried out on paraffin-embedded tru-cut prechemotherapy
biopsies. In total, 3-mm sections from 44 breast cancer samples
were mounted on Polysine microslides. For antigen retrieval,
dewaxed and rehydrated sections were immersed in Reveal buffer
(BioCarta, Hamburg, Germany) and boiled in a pressure cooker
(103kPa/15psi for 5min). After blocking nonspecific binding sites,
sections were immunoreacted with primary AB over night at 41C.
Primary AB were directed at Endothelin-1 (Affinity BioReagents,
Golden, USA, diluted 1:500), Endothelin-A-Receptor, ETAR, and
Endothelin-B-Receptor, ETBR (both from Alexis, Gru ¨nberg,
Germany, diluted 1:400). Sections were then treated for 10min
with methanol containing 0.6% H2O2 to quench endogenous
peroxidase. Bound primary mouse AB to Endothelin-1 was
detected using DAKO Mouse-EnVision-HRP. Bound primary
sheep AB to ETAR and ETBR were detected using DAKO Rabbit-
EnVision-HRP, via bridge AB rabbit-anti-sheep (Dianova, Ham-
burg, Germany, 1:50). HRP label was visualised with NovaRed
substrate kit (Vector Laboratories, Burlingame, CA, USA). Prostate
cancer tissue known to express ETAR and smooth muscle tissue
with ETB receptor activity served as positive controls.
Negative controls with omission of primary AB were included.
After nuclear counterstaining with haematoxylin, cytoplasmic
immunostaining intensity was categorised semiquantitatively into
four groups as described previously (Wu ¨lfing et al, 2003): negative
(score 0): no staining at all; weakly positive (score 1þ): faint/
barely perceptible cytoplasmic staining in the majority of the
tumour cells; moderately positive (score 2þ): a moderate
cytoplasmic staining in the majority of the tumour cells and
strongly positive (score 3þ): a strong cytoplasmic staining of the
majority of the tumour cells. The final score was designated as
negative or positive as follows: score of 0–1, negative; and score of
2–3, positive.
Data analysis
Staining results were evaluated semiquantitatively in a blind
manner. Statistical analysis was performed using SPSS 10.0
statistical software. Correlations between ET expression in
breast carcinomas and clinical or pathological response to
neoadjuvant chemotherapy were tested by cross-tables
applying w
2 test. Also, expression of ET-1, ETAR and ETBR
was correlated to each other and to classic prognostic factors with
use of w
2 test. For the analysis of response prediction, clinical
response and pathological response were divided into two
categories: ‘response’ [CRþPR] and ‘nonresponse’ [NC]. Then
associations between expression of the ET axis and response to
chemotherapy were tested with logistic regression model with the
tested factors regarded as continuous variables. The level of
significance was Pp0.05.
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lRESULTS
Immunohistochemical ET-1-, ETAR-, and ETBR-expression
Immunolabelling for ET-1, ETAR, and ETBR presented as
homogenous cytoplasmic staining. Intensity of ET-1, ETAR,
and ETBR staining among different tumours varied from
complete absence of staining to strong diffuse staining. Moderate
or strong staining intensity defined as ‘positive’ immunore-
action was present for ET-1 in 24 out of 39 (61.5%), for ETAR
in 14 out of 40 (35.0%), and for ETBR in 14 out of 39
(35.9%) evaluable breast carcinomas (Figure 1). Strong stromal
immunostaining was frequently detected in ETR-positive
but not in ETR-negative cases. We observed a close and
significant concordance between expression of ETAR and
ETBR( P¼0.013) and between ETAR and ET-1 (P¼0.021)
in breast cancers. No significant association between expres-
sion of ET-1 and ETBR( P¼0.173) was found, although
ET-1-positive tumours showed a trend towards ETBR positivity
(Table 2).
Correlation between expression of ET axis and clinical and
tumorbiological factors The relationship among the expression
of the ET axis and clinical characteristics of the breast carcinomas
prior to chemotherapy is depicted in Table 3. We observed no
significant correlation between expression patterns of the ET axis
with tumour size, lymph node involvement, or histological
grading. Comparison between ET axis and tumorbiological factors
revealed a strong inverse relationship between ET-1 expression
and the steroid hormone receptor status (ER, P¼0.031; PgR,
P¼0.006) (Table 2). Both steroid hormone receptors correlated
positively with each other (Po0.001). ETAR expression, ER- and
PgR-status were inversely correlated with proliferation rate as
assessed by Ki67.
Response to neoadjuvant chemotherapy
Treatment activity All 44 investigated patients completed treat-
ment according to the study protocol. The clinical response could
not be determined in one patient (2.3%). At the end of the
chemotherapy administration, eight patients (18.6%) attained a
clinical CR (cCR) and 17 patients (39.5%) attained a clinical PR
(cPR), for an overall clinical response rate of 58.1%. In total, 18
patients (41.9%) showed clinically NC (cNC), and no patient
progressed. Information on pathological response was available for
all patients. One patient (2.3%) was found to have a pathological
CR (pCR) and 31 patients (70.5%) had a pathological PR (pPR).
Thus, the overall pathological response rate was 72.7%. In all, 12
patients (27.3%) showed pathological NC (pNC).
Relationship between expression of ET axis and clinical
response Table 4 shows the clinical response to chemotherapy
stratified with respect to the ET-1-, ETAR-, and ETBR-status. In
total, 53.8% of ETAR-positive patients showed cNC as compared to
26.9% of ETAR-negative patients. Similarly, overall response to
chemotherapy was more common in ETAR-negative than in ETAR-
positive patients (73.1 vs 46.2%, respectively), although this
difference did not reach statistical significance (P¼0.098). No
correlation was observed between ET-1 and ETBR-status and
clinical response rate.
Relationship between expression of ET axis and pathological
response Differential expression of the ET axis with respect to
pathological response is summarised in Table 5. Pathological
response to chemotherapy was significantly decreased in ETAR-
positive patients (P¼0.002). Pathological NC was obtained in 50%
of ETAR-positive patients as compared to 7.7% of ETAR-negative
patients. None of the ETAR-positive patients had a pCR. Similar to
ETAR, ETBR expression correlated with nonresponse (42.9%),
Figure 1 Representative immunohistochemical staining patterns for ET-1 (A), ETAR( B) and ETBR( C) in breast carcinomas. For each marker, a sample
with weak (left), moderate (middle), and strong (right) cytoplasmic immunostaining is shown.
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lalthough statistical significance was not reached (P¼0.065). No
significant correlation was observed for ET-1 expression and
pathological response
Predictive value of ET axis expression for response Multivariate
analysis was performed by logistic regression to evaluate the
predictive role of ET-1, ETAR, and ETBR status for clinical and
pathological response. Clinicopathological factors associated with
prognosis such as tumour size, lymph node status, grading, and
steroid hormone receptor status were included for analysis. None
of the investigated factors, ET-1, ETAR, or ETBR, had a predictive
value for clinical response. Conversely, ETAR expression retained
independence in predicting response, showing a significant inverse
association with pathological response to treatment (P¼0.009).
Neither ET-1 (P¼0.403) nor ETBR( P¼0.056) expression was a
significant obstacle to pathological response.
Treatment arms Statistical analysis stratified for both treatment
arms showed no differences between arm A and arm B concerning
distribution of histopathological characteristics, expression of ET
axis and response rates to chemotherapy.
DISCUSSION
The indication for treating breast cancer with chemotherapy is
generally based on clinical and tumorbiological characteristics
such as lymph node involvement, hormone receptor status, and
Her-2/neu expression, which are indicators of prognosis but do
not necessarily indicate likelihood of response. To date, there is no
reliable marker for the prediction of chemotherapy response in
breast cancer patients to facilitate individualised treatment. This
study highlights the potential clinical role of ETBR and especially
of ETAR as predictors of response to neoadjuvant chemotherapy in
patients with locally advanced breast cancer.
Previously, we have demonstrated that elevated ET-1, ETAR, and
ETBR expression is more common in breast cancers of patients
with diminished disease-free and overall survival. In that study we
also observed a close correlation between ETAR-positive tumours
and clinicopathological markers for poor prognosis (Wu ¨lfing et al,
2003). To assess whether the ET axis may influence breast cancer
response to chemotherapy treatment, a series of patients with
locally advanced breast cancer was evaluated.
In this study, we found that overexpression of the ET receptors
was correlated with pathological NC following chemotherapy, thus
providing evidence that overexpression of the ET receptors may
adversely affect response to chemotherapy treatment. Higher
pathological response rates in ETBR- and especially in ETAR-
negative than in ET receptor-positive patients further support the
hypothesis that ET receptor expression is associated with
resistance to chemotherapy. Our data also suggest a potential
ability of ET receptor expression to predict breast cancer
Table 2 Significance of the correlations between various factors given as
P’s (w
2-test)
ETAR
a ETBR
a ER
b,d PgR
c,d Her-2/neu
e Ki67
d p53
e
ET-1
a 0.021 0.173 0.031 0.006 0.630 0.258 0.630
ETAR
a 0.013 0.145 0.184 0.416 0.045 0.416
ETBR
a 0.219 0.270 0.459 0.415 0.351
ER
b,d o0.001 0.245 0.008 0.695
PgR
c,d 0.865 0.001 0.698
Her-2/neu
e 0.169 0.553
Ki67
d 0.790
aImmunohistochemistry given as staining intensity.
bER¼oestrogen receptor status.
cPgR¼progesterone receptor status.
dImmunohistochemistry given as percentage of
positively stained cells (ER and PgR, X10% of tumour cells stained positive; Ki67,
X18% of tumour cell nuclei stained).
eImmunohistochemistry given as staining index
(X10% of tumour cells stained positive with at least moderate intensity).
Table 3 Relationship among ET-1, ETAR, and ETBR positive tumours and clinical/biological characteristics of breast carcinomas prior to neoadjuvant
chemotherapy
ET-1 positive (n¼39) P ETAR-positive (n¼40) P ETBR-positive (n¼39) P
T
T2 19/34 (55.9%) 0.232 11/35 (31.4%) 0.190 12/34 (35.3%) 0.414
T3 3/3 (100%) 2/3 (66.7%) 1/3 (33.3%)
T4 1/1 (100%) 1/1 (100%) 1/1 (100%)
Missing 1 1 1
N
N0 12/24 (50%) 0.082 7/24 (29.2%) 0.391 7/22 (31.8%) 0.715
N+ 11/14 (78.6%) 6/14 (42.9%) 6/16 (37.5%)
Missing 1 2 1
G
a
G1 — 0.281 — 0.436 1/1 (100%) 0.157
G2 5/10 (50%) 2/10 (20%) 2/11 (18.2%)
G3 15/22 (68.2%) 9/23 (39.1%) 9/21 (42.9%)
Missing 7 7 6
aGrading of surgical resection specimens postchemotherapy.
Table 4 Clinical response to neoadjuvant chemotherapy with respect to
expression of ET-1, ETAR, and ETBR
Clinical response
n
a CR
b PR NC P
1 P
2
ET-1
Negative 15 20% (3/15) 46.7% (7/15) 33.3% (5/15)
Positive 23 21.7% (5/23) 39.1% (9/23) 39.1% (9/23) 0.897 0.717
ETAR
Negative 26 23.1% (6/26) 50% (13/26) 26.9% (7/26)
Positive 13 15.4% (2/13) 30.8% (4/13) 53.8% (7/13) 0.255 0.098
ETBR
Negative 25 20% (5/25) 40% (10/25) 40% (10/25)
Positive 13 23.1% (3/13) 38.5% (5/13) 38.5% (5/13) 0.976 0.604
aOne patient missing in evaluation for clinical response.
bCR¼complete response;
PR¼partial response; NC¼no change. P
1¼CR vs PR vs NC (w
2 test). P
2¼response
(CR+PR) vs nonresponse (NC) (w
2 test).
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of ETAR expression for pathological response was confirmed
applying logistic regression. Similar to these findings, analysis of
clinical response to neoadjuvant chemotherapy with respect to ET
expression revealed a reduced effect in ETAR-positive patients as
compared to ETAR-negative patients although differences between
these groups were less obvious. To determine whether our results
were merely a reflection of differences between distinct groups, we
evaluated whether tumorbiological factors with well-established
prognostic relevance were related to ET-1, ETAR, and ETBR
expression. Except for a statistically significant inverse relation-
ship between ET-1 expression and steroid hormone receptor status
as well as between ETAR expression and proliferation index (Ki67),
with respect to conventional prognostic markers no further
significant correlations were found.
Accumulating data have shown that ET-1 acting through ETAR
functions as a survival factor for carcinoma cells. In colon
carcinoma cells, ET-1 inhibits apoptosis mediated by Fas-ligand
(FasL), which induces cell death via caspase activation, or
Paclitaxel (Eberl et al, 2000a,b). Similarly, in ovarian carcinoma
cells, paclitaxel-induced apoptosis is inhibited by ET-1 (via ETAR),
triggering antiapoptotic signalling through bcl-2-dependent and
phosphatidylinositol 3-kinase-mediated AKT pathways (Vacca
et al, 2000). Conversely, cervical cancer cell growth in vivo could
be stopped by ETAR blockade with Atrasentan (ABT-627), a
selective ETAR-inhibitor, alone, and in that study Atrasentan
displayed additive antitumour effects when administered in
combination with the cytotoxic agent Paclitaxel (Bagnato et al,
2002). Also, in ovarian carcinoma xenograft models, inhibition of
tumour growth by Atrasentan was found to be as effective as
Paclitaxel (Rosano et al, 2003). Since it is conceivable that
antiapoptotic factors may contribute to resistance to antitumoral
therapy, the observed chemotherapy resistance in ET receptor
overexpressing tumours may be attributed to the autocrine
influence of ET-1 acting via ETAR.
From the evidence to date, it appears that ET-1 and ETAR
play the predominant role in malignancies. Also, selective
ETAR antagonism provides the most likely method of ET axis
inhibition in cancer (Grant et al, 2003; Nelson et al, 2003). Our
findings may reflect the pivotal role of ETAR alteration in
breast cancer. The observed higher influence of ETAR rather
than ETBR expression on chemotherapy response can be explained
in terms of data that ET-1 signalling through ETAR imparts a
survival benefit of carcinoma cells by inhibiting chemotherapy
induced apoptosis. In contrast, so far, there is no evidence from
the literature that ETBR signalling is also associated with apoptosis
inhibition.
We suggest that in breast cancer ET-1 produced by the
tumour cells acts in an autocrine mechanism via ET
receptors. The lack of correlation between ET-1 expression and
chemotherapy response could be explained by the fact that ET-1
exerts its effects through ET receptor binding. ET-1 levels and
expression may, however, not be an appropriate correlate for the
ET-1 activity at the microenvironment level. ET-1 expression may
therefore not be an adequate indicator of the activity of the ETAR
signalling. It is the expression of the ETAR that signifies the
potential antiapoptotic effects of ET-1. Also in view of the
literature, ETAR activation rather than ET-1 itself promotes
tumour progression by means of various mechanisms (Nelson
et al, 2003).
Our data support the predictive role of ETAR overexpression as
a marker of adverse pathological response to chemotherapy
treatment in breast cancer. However, generalisation of our results
may be limited by the relatively small sample size. This limitation
notwithstanding, our data could offer a valid background for
further confirmatory research.
In conclusion, our findings suggest that increased expression of
the ET receptors and especially of ETAR in breast carcinomas is
associated with resistance to chemotherapy. Furthermore, in this
cohort of patients with advanced breast cancer, the ETAR status
was an independent predictor of response to chemotherapy. Thus,
immunohistochemical analysis of ETAR expression may serve as a
convenient, low-cost technique for identifying breast cancer
patients with a poor chance of response to chemotherapy and,
therefore, potential candidates for more individualised treatments.
Since our findings can possibly be explained by an ETAR-mediated
chemotherapy resistance, combining ETAR antagonism with
conventional chemotherapy may improve the outcome of breast
cancer patients.
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